Stockreport

Cadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion [Yahoo! Finance]

Cadrenal Therapeutics, Inc.  (CVKD) 
PDF Cadrenal Therapeutics Inc. Encouraging data for CAD-1005 in Phase 2 HIT Study EOP2 scheduled for Q1 for top-priority indication Additional acute and chronic oppor [Read more]